Suncoast Equity Management Has $806,000 Stake in Edwards Lifesciences Co. (NYSE:EW)

Suncoast Equity Management raised its stake in Edwards Lifesciences Co. (NYSE:EW) by 14.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,893 shares of the medical research company’s stock after purchasing an additional 1,388 shares during the period. Suncoast Equity Management’s holdings in Edwards Lifesciences were worth $806,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Alpha Financial Partners LLC acquired a new position in Edwards Lifesciences during the 3rd quarter worth approximately $693,000. Eastern Bank bought a new stake in shares of Edwards Lifesciences during the third quarter valued at approximately $98,000. BLB&B Advisors LLC raised its position in shares of Edwards Lifesciences by 9.7% during the third quarter. BLB&B Advisors LLC now owns 4,520 shares of the medical research company’s stock worth $298,000 after purchasing an additional 400 shares during the period. Commerzbank Aktiengesellschaft FI lifted its holdings in shares of Edwards Lifesciences by 40.5% in the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 3,393 shares of the medical research company’s stock worth $224,000 after purchasing an additional 978 shares in the last quarter. Finally, Fulcrum Capital LLC lifted its holdings in shares of Edwards Lifesciences by 3.6% in the 3rd quarter. Fulcrum Capital LLC now owns 117,905 shares of the medical research company’s stock worth $7,781,000 after purchasing an additional 4,067 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.0 %

Edwards Lifesciences stock opened at $74.71 on Friday. The firm has a 50 day moving average price of $72.86 and a 200-day moving average price of $69.86. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a market capitalization of $44.06 billion, a P/E ratio of 10.72, a P/E/G ratio of 4.89 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now owns 60,372 shares in the company, valued at $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 26,489 shares of company stock worth $2,002,829. 1.29% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on EW shares. Barclays upped their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. The Goldman Sachs Group upped their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Morgan Stanley increased their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Finally, Robert W. Baird dropped their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.